A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

Daniel J. DeAngelo,Harry P. Erba,Brian A. Jonas,Michael O’Dwyer,Paula Marlton,Gerwin Huls,Jane L. Liesveld,Brenda Cooper,Bhavana Bhatnagar,Michael B. Armstrong,William E. Fogler,Mary Chen,John L. Magnani,Helen M. Thackray,Anjali S. Advani,Pamela S. Becker

A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

2019

Daniel J. DeAngelo
Harry P. Erba
Brian A. Jonas
Michael O’Dwyer
Paula Marlton
Gerwin Huls
Jane L. Liesveld
Brenda Cooper
Bhavana Bhatnagar
Michael B. Armstrong
William E. Fogler
Mary Chen
John L. Magnani
Helen M. Thackray
Anjali S. Advani
Pamela S. Becker

TPS7066Background: Binding of E-selectin (E-sel) to sialyl Lex, the E-sel ligand (E-sel-L), on the leukemic cell surface activates cell survival pathways and promotes chemotherapy resistance in AML...

Keywords:

Refractory
Cell
Pathology
Cancer research
Myeloid leukemia
Sialyl Lex
Chemotherapy
Medicine
in patient
cell survival
chemotherapy resistance
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations